PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Department of Biomedical Sciences (Pharmacology Section), University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain. Electronic address: francisco.abajo@uah.es.\', \'Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Department of Biomedical Sciences (Pharmacology Section), University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain.\', \'Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.\', \'Clinical Pharmacology Department, University Hospital La Princesa, Teófilo Hernando Institute, Autonomous University of Madrid, Institute of Health La Princesa, Madrid, Spain.\', \'Clinical Pharmacology Unit, University Hospital Ramón y Cajal (IRYCIS), Madrid, Spain.\', \'Department of Biomedical Sciences (Pharmacology Section), University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain; Department of Clinical Pharmacology, Defense Central Hospital, Madrid, Spain.\', \'Department of Clinical Pharmacology, Clinic Hospital San Carlos, Department of Pharmacology and Toxicology, Complutense University of Madrid (IdISSC), Madrid, Spain.\', \'Centre of Network Biomedical Research on Frailty and Healthy Ageing (CIBERFES), Institute of Health Carlos III, Madrid, Spain.\', \'Clinical Pharmacology Department, University Hospital Puerta de Hierro, Majadahonda, Madrid, Spain.\', \'Institute of Biomedical Research, University Hospital of Getafe, Getafe, Madrid, Spain.\', \'Geriatric Department, University Hospital of Getafe, Getafe, Madrid, Spain; Centre of Network Biomedical Research on Frailty and Healthy Ageing (CIBERFES), Institute of Health Carlos III, Madrid, Spain.\', \'Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain.\', \'Institute of Environmental Assessment and Water Research (IDAEA), Spanish Council for Scientific Research (CSIC), Barcelona, Spain.\', \'Department of Nephrology, University Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; Department of Medicine, University of Alcalá (IRYCIS), Alcalá de Henares, Madrid, Spain.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0140-6736(20)31030-810.1016/S0140-6736(20)31030-8
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 32416785
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32416785>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32416785>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all